Class Action Lawsuit for Actinium Pharmaceuticals Investors
Levi & Korsinsky, LLP is reaching out to investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) regarding an important class action securities lawsuit. This legal action addresses potential losses suffered by shareholders due to alleged fraudulent activity linked to the company.
Understanding the Class Action
This class action is designed to recover losses for investors adversely affected by claims of securities fraud occurring between designated dates. Allegations suggest that misleading statements were made about the company's ability to satisfy FDA guidelines concerning their radiotherapy product, Iomab-B.
Details of the Allegations
Specifically, the lawsuit contends that the defendants misrepresented critical data from the Phase 3 Sierra trial. Reports indicated that the data would not meet FDA standards necessary for the acceptance of the Iomab-B BLA. These misleading assertions have left investors vulnerable, as the reality lacked a solid basis.
Implications for Investors
For those who experienced losses in Actinium within the specified timeframe, it is crucial to note that the deadline to become a lead plaintiff in this class action is approaching. Stakeholders have until May 27, 2025, to express their interest in this role.
What Should Investors Do?
If you are a class member, there is no financial obligation to participate in this action. Your eligibility for potential compensation can occur without involving you as a lead plaintiff. Levi & Korsinsky strives to minimize costs for its clients.
Why Choose Levi & Korsinsky?
With over two decades of experience, Levi & Korsinsky has established a remarkable reputation by securing significant settlements for shareholders. The firm is recognized for its extensive expertise in complex securities litigation, employing a dedicated team of professionals to support its clients. Its recognition as a top-tier firm reinforces their commitment to investors.
Contact Information
For more details or to discuss your situation, reach out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Telephone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The lawsuit aims to recover losses for investors affected by alleged securities fraud related to Actinium Pharmaceuticals.
Who can participate in this class action?
Any shareholders of Actinium who suffered losses during the specified period can join the action.
Is there a cost to participate in the lawsuit?
No, if you are a class member, participation incurs no out-of-pocket costs.
What is the deadline to become a lead plaintiff?
The deadline to request lead plaintiff status is May 27, 2025.
How can I contact Levi & Korsinsky for more information?
You can contact them via telephone at (212) 363-7500 or visit their website at www.zlk.com for additional questions.
